Medicago announces research collaboration for the development of a non-influenza vaccine candidate
Medicago Inc. announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.
Under the terms of the research collaboration, Medicago will apply its transient expression system to develop a vaccine candidate for a non-disclosed target. Medicago is eligible to receive payments on achievement of specified milestones stipulated in the contract.
"We believe this collaboration represents an important validation of our scientific leadership in vaccines," said Andy Sheldon, President and CEO of Medicago. "The combination of our rapid, efficacious and cost-effective VLP vaccine technology with such an accomplished partner allows us to further demonstrate the capability of our vaccine platform and has the potential to lead to further collaborations."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.